These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27690431)

  • 1. Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4.
    Brown AW; Fisher M; Tozer GM; Kanthou C; Harrity JP
    J Med Chem; 2016 Oct; 59(20):9473-9488. PubMed ID: 27690431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Sydnone-Based Analogues of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy.
    Brown AW; Holmes T; Fisher M; Tozer GM; Harrity JPA; Kanthou C
    ChemMedChem; 2018 Dec; 13(24):2618-2626. PubMed ID: 30281922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and hit to lead optimization of novel combretastatin A-4 analogues: dependence of C-linker length and hybridization.
    Provot O; Hamze A; Peyrat JF; Brion JD; Alami M
    Anticancer Agents Med Chem; 2013 Dec; 13(10):1614-35. PubMed ID: 24261611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combretastatin A4 phosphate induces programmed cell death in vascular endothelial cells.
    Ding X; Zhang Z; Li S; Wang A
    Oncol Res; 2011; 19(7):303-9. PubMed ID: 21936400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and anti-vascular activity evaluation of ethoxy-erianin phosphate as a vascular disrupting agent.
    Yuan W; Su C; Yang X; Li Y; Cao Y; Liang X; Liu J
    J Cell Biochem; 2019 Oct; 120(10):16978-16989. PubMed ID: 31111562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status.
    Jaroch K; Karolak M; Górski P; Jaroch A; Krajewski A; Ilnicka A; Sloderbach A; Stefański T; Sobiak S
    Pharmacol Rep; 2016 Dec; 68(6):1266-1275. PubMed ID: 27686966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
    Foley KP; Zhou D; Borella C; Wu Y; Zhang M; Jiang J; Li H; Sang J; Korbut T; Ye J; Zhang X; Barsoum J; Sonderfan AJ
    J Pharmacol Exp Ther; 2012 Nov; 343(2):529-38. PubMed ID: 22837008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of thiophene and benzo[b]thiophene analogs of combretastatin A-4 and isocombretastatin A-4: A comparison between the linkage positions of the 3,4,5-trimethoxystyrene unit.
    Do CV; Faouzi A; Barette C; Farce A; Fauvarque MO; Colomb E; Catry L; Berthier-Vergnes O; Haftek M; Barret R; Lomberget T
    Bioorg Med Chem Lett; 2016 Jan; 26(1):174-80. PubMed ID: 26602281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol derivative-rich melinjo (Gnetum gnemon L.) seed extract suppresses multiple angiogenesis-related endothelial cell functions and tumor angiogenesis.
    Kunimasa K; Ohta T; Tani H; Kato E; Eguchi R; Kaji K; Ikeda K; Mori H; Mori M; Tatefuji T; Yamori Y
    Mol Nutr Food Res; 2011 Nov; 55(11):1730-4. PubMed ID: 21936049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications.
    Karatoprak GŞ; Küpeli Akkol E; Genç Y; Bardakci H; Yücel Ç; Sobarzo-Sánchez E
    Molecules; 2020 May; 25(11):. PubMed ID: 32486408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationships of constrained heterocyclic analogues of combretastatin A4.
    Arthuis M; Pontikis R; Chabot GG; Seguin J; Quentin L; Bourg S; Morin-Allory L; Florent JC
    ChemMedChem; 2011 Sep; 6(9):1693-705. PubMed ID: 21732536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel class of trans-methylpyrazoline analogs of combretastatins: synthesis and in-vitro biological testing.
    Lee M; Brockway O; Dandavati A; Tzou S; Sjoholm R; Satam V; Westbrook C; Mooberry SL; Zeller M; Babu B; Lee M
    Eur J Med Chem; 2011 Jul; 46(7):3099-104. PubMed ID: 21524832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-(3,4,5-Trimethoxyphenylselenyl)-1H-indoles and their selenoxides as combretastatin A-4 analogs: microwave-assisted synthesis and biological evaluation.
    Wen Z; Xu J; Wang Z; Qi H; Xu Q; Bai Z; Zhang Q; Bao K; Wu Y; Zhang W
    Eur J Med Chem; 2015 Jan; 90():184-94. PubMed ID: 25461319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antineoplastic agents. 509: synthesis of fluorcombstatin phosphate and related 3-halostilbenes(1).
    Pettit GR; Minardi MD; Rosenberg HJ; Hamel E; Bibby MC; Martin SW; Jung MK; Pettit RK; Cuthbertson TJ; Chapuis JC
    J Nat Prod; 2005 Oct; 68(10):1450-8. PubMed ID: 16252907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4,5-Diaryl-3-aminopyrazole derivatives as analogs of Combretastatin A-4: synthesis and biological evaluation.
    Liu T; Cui R; Chen J; Zhang J; He Q; Yang B; Hu Y
    Arch Pharm (Weinheim); 2011 May; 344(5):279-86. PubMed ID: 21290430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
    Siemann DW; Chaplin DJ; Walicke PA
    Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects.
    Barrett I; Carr M; O'Boyle N; Greene LM; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
    J Enzyme Inhib Med Chem; 2010 Apr; 25(2):180-94. PubMed ID: 20222762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and anticancer properties of 5-arylbenzoxepins as conformationally restricted isocombretastatin A-4 analogs.
    Rasolofonjatovo E; Provot O; Hamze A; Rodrigo J; Bignon J; Wdzieczak-Bakala J; Lenoir C; Desravines D; Dubois J; Brion JD; Alami M
    Eur J Med Chem; 2013 Apr; 62():28-39. PubMed ID: 23353744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid synthesis of 4-arylchromenes from ortho-substituted alkynols: A versatile access to restricted isocombretastatin A-4 analogues as antitumor agents.
    Renko D; Provot O; Rasolofonjatovo E; Bignon J; Rodrigo J; Dubois J; Brion JD; Hamze A; Alami M
    Eur J Med Chem; 2015 Jan; 90():834-44. PubMed ID: 25528337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oxazole-bridged combretastatin A-4 analogues as potential vascular-disrupting agents.
    Mahal K; Biersack B; Schobert R
    Int J Clin Pharmacol Ther; 2013 Jan; 51(1):41-3. PubMed ID: 23259996
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.